These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 854139)

  • 1. The risk of anticoagulation in hemodialysis patients.
    Biggers JA; Remmers AR; Glassford DM; Sarles HE; Lindley JD; Fish JC
    Nephron; 1977; 18(2):109-13. PubMed ID: 854139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.
    Kalb R; Kram R; Morgera S; Slowinski T; Kindgen-Milles D
    Ther Apher Dial; 2013 Apr; 17(2):202-12. PubMed ID: 23551677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of systemic anticoagulation in patients undergoing angioaccess surgery.
    D'Ayala M; Smith RM; Martone C; Briggs W; Deitch JS; Wise L
    Ann Vasc Surg; 2008 Jan; 22(1):11-5. PubMed ID: 18055171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric patients undergoing arteriovenous fistula surgery without intraoperative heparin.
    Regus S; Almási-Sperling V; Lang W
    J Vasc Access; 2016 Nov; 17(6):494-498. PubMed ID: 27646929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders.
    Bajo MA; del Peso G; Jiménez V; Aguilera A; Villar A; Jiménez C; Selgas R
    Adv Perit Dial; 2000; 16():170-3. PubMed ID: 11045286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimizing hemorrhagic complications in dialysis patients.
    Lohr JW; Schwab SJ
    J Am Soc Nephrol; 1991 Nov; 2(5):961-75. PubMed ID: 1760540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essentials of anticoagulation in hemodialysis.
    Fischer KG
    Hemodial Int; 2007 Apr; 11(2):178-89. PubMed ID: 17403168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodialysis without anticoagulation.
    Sanders PW; Taylor H; Curtis JJ
    Am J Kidney Dis; 1985 Jan; 5(1):32-5. PubMed ID: 3881017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?
    Sood MM; Komenda P; Sood AR; Rigatto C; Bueti J
    Chest; 2009 Oct; 136(4):1128-1133. PubMed ID: 19809054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of point-of-care International Normalized Ratio to laboratory International Normalized Ratio in hemodialysis patients taking warfarin.
    Hoel RW; Albright RC; Beyer LK; Santrach PJ; Magtibay DL; Everson SL; McBane RD
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):99-104. PubMed ID: 18987294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic anticoagulation considerations in chronic kidney disease.
    Dager WE; Kiser TH
    Adv Chronic Kidney Dis; 2010 Sep; 17(5):420-7. PubMed ID: 20727512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.
    Shen JI; Montez-Rath ME; Lenihan CR; Turakhia MP; Chang TI; Winkelmayer WC
    Am J Kidney Dis; 2015 Oct; 66(4):677-88. PubMed ID: 26162653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of systemic anticoagulation in patients undergoing vascular access surgery.
    Bhomi KK; Shrestha S; Bhattachan CL
    Nepal Med Coll J; 2008 Dec; 10(4):222-4. PubMed ID: 19558057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhage during high-risk hemodialysis using controlled heparinization.
    Swartz RD
    Nephron; 1981; 28(2):65-9. PubMed ID: 7290274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.